

(CIN:L24232GJ1996PLC029894)



Date: 02 February 2024

To, The General Manager, Corporate relationship department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400 001 Scrip Code: 543321 Ref. No.: TCPCL/SEC/2023-24/00095

The Manager, Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra(E), Mumbai-400 051 Scrip Symbol: TATVA

Subject: Intimation of Schedule of Meeting with Investor

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we hereby submit schedule of investor meeting that the Company would be participating:

Date	Investor	Туре	Mode
07 February 2024	Dymon Asia	One on One Meeting	Virtual Meeting

Please note that the above is subject to change, if any.

The Company will be referring to publicly available information for discussions during interaction in the meeting.

No confidential / unpublished price sensitive information (UPSI) will be shared during the meeting.

The above information shall be made available on the website of the Company at www.tatvachintan.com.

Kindly take the above intimation on your record and oblige.

Thanking You,

Yours Faithfully, For Tatva Chintan Pharma Chem Limited

Ishwar Nayi Company Secretary and Compliance Officer M. No.: A37444

Registered Office and Factory: Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.
Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.
Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.
Telephone No. : +91 75748 48533 / 34 Fax : +91 265 263 8533 E-mail : cs@tatvachintan.com Website : www.tatvachintan.com